Investment
Features
FeesSafety
Academy
More
Pluang+

Aritzia expected to beat Q2 EPS forecasts with strong sales momentum, UBS says

Analyst Insights
29 Sep 2026
Proactive Investors
View Source
Bullish
Aritzia expected to beat Q2 EPS forecasts with strong sales momentum, UBS says

UBS expects Aritzia to surpass second-quarter earnings per share forecasts by $0.05, driven by strong sales momentum continuing into the third quarter. The brokerage anticipates a solid third-quarter outlook and reaffirmation of fiscal 2027 revenue growth and adjusted EBITDA margin guidance despite tougher second-half comparisons and macroeconomic uncertainty. Data shows significant growth in website visitors and sales in the US and Canada, with reduced promotional activity. UBS maintains a "buy" rating and a C$216 price target, expecting the company's growth to drive outperformance.

Aritzia's expected Q2 EPS beat by $0.05 is notable alongside Pluang's Consumer Cyclical sector data. For readers following US consumer cyclical stocks, here is Pluang's market snapshot as of Sep 30, 2026 00:02 WIB: out of 112 priced stocks, 33 rose and 78 fell. Notable movers include MBLY at USD 7.55 with a 3.08% decline and 100% buy order activity, RSI at USD 20.13 up 2.97%, and LULU at USD 97.63 down 2.93% with 59% sell orders and a typical hold time of 104 days.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
18 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
First Financial Bank to open new full-service branch in Bee Cave, Texas, expanding in Austin area.

First Financial Bank to open new full-service branch in Bee Cave, Texas, expanding in Austin area.

First Financial Bank, a subsidiary of First Financial Bankshares, Inc., announced it will open a new full-service branch in Bee Cave, Texas, in late October. This marks the bank's 81st location and strengthens its presence in Central Texas and the gr...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App